` BLRX (BioLine RX Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

B
BLRX
vs
T
Tel Aviv 355

Over the past 12 months, BLRX has underperformed Tel Aviv 355, delivering a return of -35% compared to the Tel Aviv 355's +59% growth.

Stocks Performance
BLRX vs Tel Aviv 355

Loading
BLRX
Tel Aviv 355
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BLRX vs Tel Aviv 355

Performance Gap Between BLRX and TA35
HIDDEN
Show

Performance By Year
BLRX vs Tel Aviv 355

Loading
BLRX
Tel Aviv 355
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
BioLine RX Ltd vs Peers

Tel Aviv 355
BLRX
RYI
AVGR
BROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

BioLine RX Ltd
Glance View

Market Cap
34.4m ILS
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
HIDDEN
Show
Back to Top